Published on : Dec 11, 2017
Albany, New York, December 11, 2017: Hemophilia A and B are inherited bleeding disorders caused by the deficiency of blood clotting factor VIII (FVIII) or factor IX (FIX), respectively. It is affecting more than 400,000 people worldwide. Considering this fact, novel treatments for people suffering from hemophilia and other different bleeding problems has evolved over the past. With a prime focus on Asia-Pacific Market, a study titled “Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023” has been broadcasted to the online repository of Market Research Hub (MRH). The report aims to provide detailed analysis of therapeutics market along with pipeline landscape. In addition, research analyzes the hemophilia A and B pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel treatment approaches.
In terms of geography, analysts anticipate levels of hemophilia A and B market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as coverage of the individual contributions of promising late-stage molecules to market growth. It has been clearly stated in the study that patients with hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and therefore represent a strong market opportunity. As per the study key findings, Asia-Pacific hemophilia A market will be valued at $1,499.2m in 2023, growing from $838.9m in 2016, at a compound annual growth rate of 8.6%. The report also adds that this growth is mainly driven by rising treatment receiving pool, launch of long-acting replacement therapies and non-factor therapy.
Basically, hemophilia is serious bleeding disorder as it is inherited from the parents to their offspring, it is a condition in which, an individual’s blood is unable to clot in an appropriate manner due to deficiency or absence of some clotting factor in the blood that sometimes further leads to uncontrolled bleeding which can occur spontaneously. It has been analyzed that Hemophilia A is four to six times as common as hemophilia B, and more than half of hemophilia A patients have a severe form of hemophilia, therefore effective treatment methods are essential. The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods.
Moreover, the research also explains the overview of marketed products for hemophilia A and B. The current marketed products landscape comprises replacement factor therapies, including recombinant therapies and new long-acting recombinant products. The impact of the new long-acting recombinant factor VIII and recombinant factor IX product are also mentioned in the study. In addition, clinical trials analysis has been presented.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1389105
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com